Compare TARA & JFIN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | TARA | JFIN |
|---|---|---|
| Founded | N/A | 2011 |
| Country | United States | China |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Finance: Consumer Services |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 292.9M | 247.1M |
| IPO Year | 2014 | 2018 |
| Metric | TARA | JFIN |
|---|---|---|
| Price | $5.47 | $4.87 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 5 | 0 |
| Target Price | ★ $24.40 | N/A |
| AVG Volume (30 Days) | ★ 572.7K | 41.2K |
| Earning Date | 05-01-2026 | 06-03-2026 |
| Dividend Yield | N/A | ★ 17.47% |
| EPS Growth | ★ 38.25 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $2,948,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $1.35 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.77 | $3.70 |
| 52 Week High | $7.82 | $18.70 |
| Indicator | TARA | JFIN |
|---|---|---|
| Relative Strength Index (RSI) | 55.16 | 52.32 |
| Support Level | $4.92 | $3.70 |
| Resistance Level | $5.47 | $5.00 |
| Average True Range (ATR) | 0.26 | 0.20 |
| MACD | 0.05 | 0.09 |
| Stochastic Oscillator | 72.46 | 78.33 |
Protara Therapeutics Inc is a clinical-stage biopharmaceutical company focused on advancing its therapies for the treatment of cancer and rare diseases. Its drug development pipeline includes: TARA-002, an investigational cell therapy in development for the treatment of non-muscle invasive bladder cancer (NMIBC) and lymphatic malformations (LMs); and IV Choline Chloride, an investigational phospholipid substrate replacement therapy, for patients receiving parenteral support, or PS, which includes both nutrition and fluids.
Jiayin Group Inc is China's technology service group. It is an enterprise engaged in technological innovation services. It is committed to using big data, cloud computing, artificial intelligence and other technologies to connect consumers and financial institutions in consumption scenarios so that every user can enjoy efficient and convenient technology services. The company has engraved technological innovation into the company's development genes since its establishment, adheres to the dual drive of digital plus technology, and focuses on building a cloud service platform and intelligent risk control system with big data drive as the core concept.